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 Acute liver injury is a crippling disorder accompanied by extensive impairment of 
liver’s synthetic, metabolic and detoxifying functions. Tiron is a synthetic vitamin E 
analog, proven to be anti-oxidant. This study was undertaken to investigate the 
protective activity of tiron against thioacetamide (TAA)-induced acute liver injury. 
Rats were orally treated with tiron (300 mg/kg) for eight days prior to I.V. TAA 
either (70 mg/kg) or (280 mg/kg) to induce acute liver injury. Biochemical 
evaluation of hepatotoxicity indices, oxidative stress, cytotoxicity and inflammatory 
marker: interleukin-6 (IL-6) was conducted along with histopathological 
examination. Meanwhile, tiron was found to mitigate the TAA-induced elevation of 
ALT, AST and ALP. However, serum albumin levels mildly improved. Tiron restored 
liver GSH contents and maintained liver SOD activity. Moreover, tiron significantly 
reduced the level of serum IL-6. In context, histopathological examination revealed 
that tiron slightly reduced the extent of TAA-induced necrosis. Tiron has manifested 
the observed hepatoprotective effect probably by manipulating inflammatory 
response of liver to injury via downregulating the expression of inflammatory IL-6 
and alleviating oxidative stress.   
 
Key words: tiron, thioacetamide, acute liver injury, oxidative stress, necrosis, 
Interleukin-6. 
 
1.  Introduction 
The liver is a vital organ that performs a wide 
array of functions including biotransformation and 
metabolism and excretion of endogenous and 
exogenous compounds, synthesis of various plasma 
proteins and storage of glycogen (Cemek et al., 2010). 
Acute liver failure (ALF) is a debilitating disorder 
that can quickly result in multiorgan failure and death 
(Bernal and Wendon, 1999). Viral-induced hepatitis and 
drug or toxin-induced liver injuries are among the main 
causes of ALF (Gill and Sterling, 2001). ALF is 
characterized by loss of hepatic mass and deterioration 
of hepatocytes functions which may result in coma and 
death if not managed right away (Newsome et al., 
2000). 
The human body cannot dispense with 
inflammation as an immune system response to any 
injury. Although inflammation combats virulent 
microbes and toxins, it can inflict detrimental impacts 
on the host (Medzhitov, 2010). Therefore, regulation of 
cytokine expression is a major concern when tackling 
inflammation (Dayer, 2003). Typically, increased 
oxidative stress has been claimed to induce cytotoxicity 
(Han et al., 2006).  
Thioacetamide is a hepatotoxin which has been 
repeatedly utilized to experimentally induce ALF in rats 
(Bautista et al., 2010; Chen et al., 2008; Shapiro et al., 
2006). TAA has been reported to induce acute liver 
injury, liver fibrosis, cirrhosis and hepatocellular 
carcinoma and to mimic the features of hepatitis C 
infection in human (Abdelaziz et al., 2015; Alshawsh et 
al., 2011; Mormone et al., 2012; Said et al., 2013). Two 
dose levels of TAA 70 mg/kg and 280 mg/kg were used 
to induce liver injury to assess the hepatoprotective 
potential of tiron against different extents of TAA-
induced acute liver injuries. 
Tiron is a synthetic analog of vitamin E. However, 
tiron is water-soluble in contrast to vitamin E (Zafarullah 
et al., 2003). Vitamin E has reportedly demonstrated 
protection against experimentally induced non-alcoholic 
steatohepatitis via improving liver functions and 
mitigating the inflammatory response in liver (Gitto et 
al., 2015).   
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Tiron has been reported to be an effective 
antidote for vanadyl sulphate intoxication in liver and 
kidney of mice (Gomez et al., 1991), and to mitigate 
bortezomib-induced poly (ADP-ribose) polymerase 
protein breakage and apoptosis in human lung cancer 
cells (Ling et al., 2003). Also, tiron has shown anti-
apoptotic effect on melanoma cells in humans (Yang et 
al., 2007).  
The current investigation was undertaken to 
assess the hepatoprotective potential of tiron against 
thioacetamide-induced acute liver failure. Hepatocytes’ 
integrity, hepatic synthetic and excretory functions 
were evaluated. Serum LDH and serum IL-6 were 
measured to assess cytoprotective and anti-inflammtory 
potentials of tiron. Hepatic reduced glutathione 
contents (GSH) and superoxide dismutase (SOD) activity 
were determined. Lastly, histopathological examination 
of liver specimens was carried out. 
 
2.  Materials and methods 
2.1.  Animals 
Thirty adult male Sprague Dawely rats; 8 weeks 
age weighing about 200 ± 20 g, were bought from the 
Experimental Research Centre of Nephrology and 
Urology Center, Mansoura University, Egypt. The 
experimental protocol complies with the ethics and 
guidelines of care and handling of experimental animals 
adopted by "The research Ethics Committee", Faculty of 
Pharmacy, Mansoura University.  
 
2.2.  Chemicals and reagents 
Tiron was purchased (Sigma- Aldrich, St. Louis, 
MO, USA), and was suspended in 0.5% 
carboxymethylcellulose (CMC) for oral administration. 
Thioacetamide was purchased (Sigma- Aldrich, St. Louis, 
MO, USA) and dissolved in 0.9% w/v NaCl (saline) for I.V. 
injection.  
 
2.3.  Experimental Design 
 Acute liver injury was induced in rats, by single 
I.V injection of TAA (70 mg/kg) and TAA (280 mg/kg), 
respectively (Chen et al., 2008). Rats were randomly 
distributed into 5 groups each comprised 6 rats. Group 
(1): Negative control: rats received the vehicle (0.2 ml of 
0.5% CMC, orally) once daily for 8 days. Group (2): TAA1 
group: rats received 0.2 ml of 0.5% CMC, orally and on 8th 
day of the experiment TAA (70 mg/kg, I.V.) (Chen et al., 
2008). Group (3): TAA2 group: rats received 0.2 ml of 
0.5% CMC, orally and on 8th day of the experiment TAA 
(280 mg/kg, I.V.) (Chen et al., 2008). Group (4): Tiron1 
group: rats received tiron (300 mg/kg, orally) (Bowes 
and Thiemermann, 1998) + TAA (70 mg/kg, I.V.) on the 
8th day of the experiment (Chen et al., 2008). Group (5): 
Tiron2 group: rats received tiron (300 mg/kg, orally) 
(Bowes and Thiemermann, 1998) + TAA (280 mg/kg, I.V.) 
on the 8th day of the experiment (Chen et al., 2008). 
Twenty four hours after TAA injection; all the rats 
were sacrificed via injection of an overdose of 
thiopental sodium (40 mg/kg). Blood samples were 
compiled from the rats under thiopental anesthesia via 
puncture of the retro-orbital plexus. The serum was 
separated and used promptly to estimate the 
biochemical parameters. 
Livers from all rats were collected, rinsed and 
weighed to calculate liver/body weight index. The left 
lobe of the liver was immediately preserved in formalin 
for histopathological examination and the right lobe of 
the liver was used for preparation of liver homogenate  
 
2.4.  Preparation of liver homogenate 
500 mg of the right lobe of the liver was weighed, 
homogenized in 1.15% KCl and centrifuged to yield 10% of 
liver homogenate. The supernatant was separated and 
referred to as liver homogenate and it was used to 
estimate ant-oxidant biomarkers: GSH and SOD.  
 
2.5.  Assessment of serum ALT, AST, albumin, ALP and 
LDH 
Serum alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and albumin were determined 
according to manufacturer’s instruction using 
commercially available kits (Biomerieux, Marcey-
L'Etoile, France). Serum ALP levels were measured using 
commercially available kits (ABC Diagnostics, Egypt). 
Serum LDH level was determined using the 
commercially available kit (biomed. Diagnostics, Egypt). 
Test procedures were conducted according to the 
provided manufacturer’s instructions. 
 
2.6.  Assessment of hepatic content of GSH and 
hepatic SOD activity 
SOD activity and GSH content in liver 
homogenate were determined using commercially 
available kit (Biodiagnostic, Giza, Egypt). Test 
procedures were undertaken in accordance with the 
provided manufacturer’s instructions.  
 
2.7.  Assessment of serum IL-6 levels 
Serum IL-6 was measured using commercial 
ELISA assay kit (RayBio, Norcross, USA). The 
concentration was expressed as pg/ml. methodology of 
determination was conducted according to the supplied 
manufacturer’s instructions. 
 
2.8.  Histopathological examination 
The left lobe of the livers from all rats were 
collected and dipped in ice-cold saline solution, fixed in 
10% neutral buffered formalin solution.  Specimens were 
immersed in paraffin and cut into sections (4 to 5 μm) 
thickness slides.  The slides were stained with 
hematoxylin and eosin (H&E) and examined under a 
microscope randomly and the histopathologist was 
blinded to the experimental groups. 
 
2.9.  Statistical analysis 
One-way analysis of variance (ANOVA) followed 
by Tukey Kramer’s test was run, where data was 
demonstrated as mean ± standard error (SE). GraphPad 
Instat version 3.06 software program was used to 
statistically analyze data. Graphs were drawn by 
GraphPad Prism (ISI® software, USA) version 5 
software. 
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3.   Results and Discussion 
Effect of tiron (300mg/kg) administration orally 
for 8 days on TAA (70 mg/kg) and TAA (280 mg/kg)-
induced acute liver injury. 
 
3.1.   Liver/body weight Index: 
I.V. TAA (70 mg/kg) and TAA (280 mg/kg) 
significantly increased liver/body weight indices by 
approximately 1.2 and 1.15 fold respectively in 
comparison to healthy control group, figure (1). Oral 
tiron (300 mg/kg) for 8 days substantially reduced the 
liver/body weight index by nearly 10% in comparison to 
TAA (70 mg/kg) diseased control. Conversely, oral tiron 
(300 mg/kg) for 8 days failed to produce a significant 
reduction in the liver/body weight index when 
compared to TAA (280 mg/kg) diseased control, figure 
(1).  
 
3.2.  Serum ALT and AST: 
Significant elevation in serum ALT and AST, by 
about 5.5 and 1.93 fold was noticed following I.V. TAA 
(70 mg/kg), table (1).  Meanwhile, significant increase in 
serum ALT and AST by 6.7 and 2.4 respectively was 
observed in TAA (280 mg/kg) diseased control, table (1).  
Daily oral treatment with tiron (300 mg/kg) for 8 
days significantly decreased the elevated serum ALT 
levels by approximately 34.5%, but failed to produce 
concomitant significant reduction in serum AST 
compared to TAA (70 mg/kg) control, table (1). Similarly, 
oral tiron (300 mg/kg) for 8 days significantly lowered  
serum ALT and AST levels; by about 21% and 44% in 
comparison to TAA (280 mg/kg) diseased control, table 
(1). 
 
3.3.  Serum albumin and ALP 
As shown in table (1), I.V. TAA (70 mg/kg)          
and (280 mg/kg) markedly reduced serum albumin 
levels to about three quarters (3/4) and two thirds (2/3) 
the value of albumin in the healthy control groups 
respectively. 
 Oral tiron (300 mg/kg) once daily for 8 days 
failed to elicit a remarkable increase in serum albumin 
compared to either TAA (70 mg/kg) or TAA (280 mg/kg) 
diseased groups, table (1).  
In context, as illustrated in table (1), I.V. TAA (70 
mg/kg) and (280 mg/kg) elicited approximately a 1.3 and 
1.6 fold significant increase in serum ALP respectively in 
comparison to the healthy control group. Daily oral tiron 
(300 mg/kg) for 8 days significantly lowered the 
increased serum ALP levels by 17.8% and 38% in 
comparison to TAA (70 mg/kg) and TAA (280 mg/kg) 
diseased groups respectively, table (1). 
 
3.4.  Serum LDH 
As represented in table (2), I.V. TAA (70 mg/kg) 
and (280 mg/kg) resulted in a 1.8 and 1.6 fold increase 
respectively in serum LDH level in comparison to 
negative control group.  
Oral tiron (300 mg/kg) for 8 days prior to TAA (70 
mg/kg) restored serum LDH to   normal levels,  table  (2).  
Table 1: Effect of daily oral tiron (300mg/kg) for 8 days on serum ALT, AST, albumin and ALP in rats subjected to I.V. 
Thioacetamide (70 mg/kg) or (280 mg/kg) 
 
Groups ALT (Unit/ml) AST  (Unit/ml) Albumin (g/dl) ALP (U/L) 
Healthy Control (0.2 ml of  CMC , orally) 41.42±3.48 133.91±11.49 2.67±0.23 387.2±27.6 
TAA1 (70 mg/kg, I.V.) 228.13±15.76* 257.95±10.09* 1.78±0.14* 493.4±12.5* 
Tiron1: (300 mg/kg, orally) /TAA (70 mg/kg, I.V.) 149.45±5.56*† 205.19±10.69* 1.55±0.06* 405.4±9.2† 
TAA2 (280 mg/kg, I.V.) 281.75±10.46* 315.68±7.88* 1.48±0.07* 599.4±24.8* 
Tiron2: (300 mg/kg, orally) /TAA (280 mg/kg, I.V.) 222.73±13.31*# 175.42±13.03# 1.95±0.12 373.4±11.1# 
 
Tiron (300 mg/kg) was orally administered for 8 days prior to I.V. Thioacetamide (70 mg/kg) or (280 mg/kg). The rats were sacrificed 24 
hours later. Statistical analysis was performed using ANOVA followed by Tukey–Kramer test. 
Data are expressed as the mean ± SEM (n=6). *: Significantly different vs. negative control at P<0.05; †: Significantly different vs. 
corresponding TAA1 group at P<0.05; #: Significantly different vs. corresponding TAA2 group at P<0.05. 
 
Table 2: Effect of daily oral tiron (300mg/kg) for 8 days on serum LDH and serum IL-6 levels in rats subjected to I.V. 
Thioacetamide (70 mg/kg) or (280 mg/kg) 
 
Groups IL-6 (pg/ml) LDH (U/L) 
Control (CMC) group (0.2 ml of CMC , orally) 4.0 ± 0.12 1502.53 ± 137.98 
TAA1 (70 mg/kg, I.V.) 6.9 ± 0.31* 2707.61 ± 66.03* 
Tiron1: TAA (70 mg/kg, I.V.) /tiron (300 mg/kg, orally) 5.8 ± 0.07*† 1629.31 ± 52.27† 
TAA2 (280 mg/kg, I.V.) 8.4 ± 0.44* 2355.65 ± 59.98* 
Tiron2: TAA (280 mg/kg, I.V.) /tiron (300 mg/kg, orally) 4.1 ± 0.35# 1940.78 ± 112.61 
 
Tiron (300 mg/kg) was orally administered for 8 days prior to I.V. Thioacetamide (70 mg/kg) or (280 mg/kg). The rats were sacrificed 24 
hours later. Statistical analysis was performed using ANOVA followed by Tukey–Kramer test. 
Data are expressed as the mean ± SEM (n=6); *: Significantly different vs. negative control at P<0.05; †: Significantly different vs. 
corresponding TAA1 group at P<0.05; #: Significantly different vs. corresponding TAA2 group at P<0.05. 
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Figure (1): a.Effect of tiron (300mg/kg) administration 
orally for 8 days on liver/body weight index; b. Effect of 
tiron (300mg/kg) administration orally for 8 days on 
hepatic GSH content; c. Effect of tiron (300mg/kg) 
administration orally for 8 days on hepatic 
SOD activity.   
 
Tiron (300 mg/kg) was orally administered for 8 days prior to 
I.V. Thioacetamide (70 mg/kg) or (280 mg/kg). Rats were 
sacrificed 24 hours later. Data are expressed as the mean ± 
SEM (n=6). Statistical analysis was performed using ANOVA 
followed by Tukey–Kramer test. *: Significantly different vs. 
negative control at P<0.05; †: Significantly different vs. 
corresponding TAA1 group at P<0.05;#: Significantly different 
vs. corresponding TAA2 group at P<0.05. 
 
However, daily oral tiron (300 mg/kg) decreased serum 
LDH levels by nearly 18% in comparison to TAA (280 
mg/kg), table (2).  
 
3.5.  Serum IL-6 
I.V. TAA (70 mg/kg) and (280 mg/kg) significantly 
elevated serum IL-6 levels by approximately 72.5% and 
110% respectively in comparison to negative control 
groups, table (2).  
 Daily oral administration of tiron (300 mg/kg) for 
8 days remarkably reduced serum IL-6 by about 16% and 
51% in comparison to TAA (70 mg/kg) and TAA (280 
mg/kg) diseased controls respectively, table (2). 
3.6.  Hepatic SOD activity and GSH contents 
Liver GSH content vigorously declined by 59% and 
81% in TAA (70 mg/kg) and (280 mg/kg) diseased 
controls respectively compared to negative control 
group figure (2).  
Oral pre-treatment with tiron (300 mg/kg) slightly 
increased GSH by nearly 39%, but in a non-significant 
way compared to TAA (70 mg/kg) diseased controls, 
figure (2). On the other hand, daily oral tiron (300 
mg/kg) for 8 days significantly elevated GSH levels by 
120% in comparison to the TAA (280 mg/kg) diseased 
group.  
In context, single I.V. TAA (70 mg/kg) and (280 
mg/kg) significantly diminished liver SOD activity by 
approximately 61% and 82% respectively in comparison 
to healthy control rats, figure (3). Oral tiron (300 mg/kg) 
for 8 days substantially protected against TAA-
intoxication and restored SOD to nearly basal levels in 
comparison to TAA diseased controls, figure (3). 
 
3.7.  Histopathological examination 
Histopathological examination of liver specimens 
of the negative control group stained with H&E revealed 
normal hepatocytes’ structure with absence of any 
evidence of injury or necro-inflammatory changes 
(figure 4: A).  
Conversely, examination of both TAA (70 mg/kg) 
and TAA (280 mg/kg) diseased controls specimen 
revealed massive bridging necrosis and centrilobular 
necrosis with more extensive injury in TAA (280 mg/kg) 
evident in  increased portal inflammation and significant 
tissue infiltration with inflammatory cells (figure 4: B, C).   
Treatment with tiron (300 mg/kg) prior to either 
TAA (70 mg/kg) or TAA (280 mg/kg) revealed slight 
reduction in necrosis with persistence of mild 
mirovesicular steatosis, centrilobular necrosis and 
moderate portal inflammatory infiltrate (figure 5: E, F). 
The current study sheds light on the potential 
significant hepatoprotective efficacy of tiron. Oral tiron 
administration in the current study resulted in 
improvement of biochemical parameters under 
investigation. It significantly improved liver functions 
and LDH. Serum albumin also improved, but not in a 
significant manner. Meanwhile, serum ALP significantly 
improved. Also, serum IL-6 significantly declined with 
tiron treatment. Hepatic SOD activity and GSH liver 
contents significantly increased after tiron treatment. 
Histopathological examination also revealed 
concomitant tissue improvement retraction of TAA-
induced necrosis. 
To date, this is the first study which investigates 
the potential hepatoprotective influence of tiron against 
TAA-induced acute liver injury and failure. Tiron has 
been proven to show protective efficacy against 
acetaminophen-induced acute liver injury and 
hepatotoxicity (Shoeib et al., 2015). 
Acute liver failure (ALF) is a complex 
multisystemic illness. It usually develops after severe 
insult to the liver. ALF is characterized by severe 
impairment of liver synthetic and metabolizing functions 
(Trey and Davidson, 1970).  
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Commonly, TAA has been administered 
intraperitoneally to induce ALF (Bautista et al., 2010). In 
the current study, TAA was administered intravenously. 
Chen et al. proposed that I.V. injection is superior to I.P, 
because the single I.V. injection of TAA doesn’t induce 
hepatic encephalopathy, renal failure, hypoglycemia or 
hypotension that can increase mortality rate (2008).  
Thioacetamide has been claimed to increase 
hepatocytes’ permeability which explains the release of 
cell content and the elevation in biochemical 
parameters: ALT, AST, ALP and LDH (Alshawsh et al., 
2011). 
TAA has also been reported to induce significant 
centrilobular hepatotoxicity. The oxidative metabolism 
of TAA yields reactive oxidative agents; thioacetamide 
sulphoxide and thioacetamide-S, S-dioxide (Chilakapati 
et al., 2005; Kucera et al., 2011). Thioacetamide-S, S-
dioxide is a very reactive compound and causes 
oxidative injury (Kwon et al., 2010; Porter and Neal, 
1978) and necrosis by targeting tissue macromolecules, 
lipids, protein, and by induction of DNA peroxidation 
(Alshawsh et al., 2011; Bruck et al., 2004). Furthermore, 
Thioacetamide-S, S-dioxide has been reported to induce 
nuclear factor kappa B (NF-κB), also resulting in 
centrilobular necrosis (Kucera et al., 2011; Shapiro et al., 
2006). Moreover, TAA has been reported to deplete 
several antioxidants that exist in the body (Bautista et 
al., 2010; Sun et al., 2000).  
Reactive oxygen species induce cell damage by 
induction of peroxidation of membrane lipids, 
denaturation of proteins -e.g enzymes and ion channels- 
and DNA injury.  Exposing cultured cells to ROS results 
in strand breakage of DNA and subsequent activation of 
the nuclear enzyme, poly (ADP-ribose) synthetase 
(PARS) (Berger, 1985; Szabo et al., 1996). This explains 
the correlation between oxidative stress, inflammation 
and acute liver injury. 
In the current study, single I.V. injection of both 
TAA (70 mg/kg) and TAA (280 mg/kg) elicited a 
significant increase in serum ALT and AST, implying 
impairment of hepatic integrity and loss of hepatocytes 
functions.  
Serum albumin has been taken an indicator to 
evaluate the synthetic ability of hepatocytes. Serum 
 
 
Figure 1. Histopathological specimen stained with H&E 
 (A): Normal healthy control revealing normal hepatic architecture, (B): TAA1 (70 mg/kg) group revealing massive hepatocyte necrosis 
with centrilobular necrosis and microvesicular steatosis (C): TAA2 (280 mg/kg) reveals massive bridging necrosis (D) Tiron1 
group revealing slight decrease in centrilobular necrosis and  and moderate portal inflammatory infiltrate  and (E) Tiron2 group reveals 
reduced necrosis.     
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albumin is not altered in mild liver injury, but 
considerably diminishes in the face of severe liver 
necrosis (Rosenthal, 1997). Rats receiving single dose of 
either TAA (70 mg/kg) or (TAA 280 mg/kg) 
demonstrated an outstanding, significant fall in 
estimated serum albumin levels confirming the 
incidence of ALF. The alterations in liver transaminases 
levels, serum ALP and serum albumin are consistent 
with previously reported patterns of TAA-induced acute 
injury (Abdelaziz et al., 2015; Alkiyumi et al., 2012; Chen 
et al., 2008). 
Meanwhile, the massive significant elevation in 
serum ALP is indicative of disruption of liver's excretory 
functions. The level of ALP usually increases in 
intrahepatic cholestasis and liver’s infiltrative diseases 
(Gaze, 2007).   
Significant elevation in serum LDH is indicative for 
tissue breakdown, cell membrane damage, loss of 
cellular contents and cytotoxicity (Balduzzi et al., 2004).  
GSH is an important endogenous antioxidant 
needed to preserve the cells’ regular redox state 
(Mantawy et al., 2012; Masella et al., 2005). There was 
substantial decrease in SOD activity and GSH liver 
content after TAA injection.. The decline in SOD activity 
is in line with Alkiyumi et al. (2012).  
The enormous decline in hepatic GSH content is 
in agreement with previous studies (Akbay et al., 1999; 
Kucera et al., 2011). TAA-induced hepatocellular injury of 
rats is partly triggered by increased oxidative stress due 
to GSH depletion (Akbay et al., 1999; Kucera et al., 2011). 
Accordingly, it can be proposed that depletion of the 
intracellular anti-oxidant defense system predisposed 
hepatocytes to disruption and in turn leakage of LDH. 
The inflammatory responses are regulated by 
proinflammatory mediators such as IL-1 and IL-6 and 
TNF-α (Medzhitov, 2010). IL-6 release has been linked to 
cell injury, because IL-6 is considered a primary 
biomarker in acute inflammatory response (Jean-
Baptiste, 2007; Saeed et al., 2012), overproduction of IL-
6 has been alleged to result from the acute liver injury 
and inflammation (Kim et al., 2014; Lacour et al., 2005).  
Kupffer cells are considered the primary cells that 
release pro-inflammatory cytokines such as IL-6 as a 
response to liver injury or inflammation (Kmiec, 2001; 
Masubuchi et al., 2003). Serum IL-6 significantly declined 
following tiron treatment and that may be associated 
with kupffer cell modulation by tiron. 
Interleukin-6 is an activator and product of NF-κB 
(Hagemann et al., 2008; Robinson and Mann, 2010). IL-6 
production is correlated with cell injury and IL-6 is 
deemed as an initial marker for acute inflammation 
(Jean-Baptiste, 2007).  
NF-κB modulates the inflammatory and immune 
response in the host by enhancing and expressing 
particular cellular genes (Cao et al., 2006; Elsharkawy 
and Mann, 2007). Stimulation of NF-κB is arranged by 
various signal transduction cascades to overcome 
diverse stress conditions such as infection and 
inflammation (O'Dea and Hoffmann, 2009). 
In this context, I.V. TAA (70 mg/kg) and TAA (280 
mg/kg) dose-dependently elevated IL-6. TAA induced 
massive bridging necrosis with inflammatory infiltrates 
mostly of leucocytes. The previous findings were in 
parallel with Kucera et al. where they found that I.P. 
TAA (100 mg/kg) increased serum levels of ALT, AST, 
ALP and IL-6 and caused necrosis in liver tissues upon 
histopathological examination (Kucera et al., 2011). 
Generally, impacts of antioxidants have been 
widely tested for the prevention and treatment of acute 
and chronic liver injuries. Some studies revealed that 
free radical scavengers are extensively beneficial in 
preventing and treating chronic liver injury (Parola et al., 
1992; Shoeib et al., 2015). 
Tiron at the investigated dose (300 mg/kg/rat) 
significantly improved hepatic impairment; particularly it 
markedly reduced serum ALT. This finding is in line with 
Bowes and Thiemermann‘s study where tiron 
attenuated the extent of ischemia/reperfusion-induced 
liver injury (Bowes and Thiemermann, 1998). 
Interestingly, tiron has been reported to confer 
significant protection against acetaminophen-induced 
acute liver injury in rats (Shoeib et al., 2015). 
GSH liver contents and SOD activity in liver 
homogenate remarkably increased, with reflection on 
liver histopathology. The improvements in ALT, ALP, 
albumin, hepatic GSH content and histopathological 
examination are similar to the study of Shrivastava and 
his colleagues (2007), where tiron demonstrated a 
profound protective efficacy against vanadium-induced 
hepatic intoxication in rats (Shrivastava et al., 2007).  
Tiron has been reported to inhibit oxaliplatin-
induced cell death in colorectal cancer cells (Shi et al., 
2012). Furthermore, tiron alleviated oxidative stress 
markers: O2
• and MDA following ischemia/reperfusion-
induced acute liver injury (Bowes and Thiemermann, 
1998). 
Tiron has been also reported to modulate survival 
of melanoma cell via mitochondria-dependent and ROS-
independent mechanisms, involving NF-κB. 
Interestingly, it has been reported that tiron chemically 
enhances NF-κB -dependent gene transcription with 
antiapoptotic effects (Yang et al., 2007). Similarly, some 
studies revealed that there was a strong correlation 
between tiron and the activation of NF-κB in melanoma 
models (Schwartz and Davidson, 2004). ROS has been 
reported to enhance NF-κB by either the activating 
protein kinase C pathway or modulating IL-6 expression 
(Ogata et al., 2000). 
Tiron has been also reported to substantially 
reverse the increase of TnI or phospho-GATA-4 protein 
expression in neonatal rat cardiomyocytes and H9c2 
cells caused by a high glucose concentration which 
helped to improve myocardial contractility mainly by 
scavenging ROS (Ku et al., 2011).  
Tiron may have demonstrated such 
cytoprotective and hepatoprotective efficacy by either 
reducing the generation of free radicals as previously 
reported (Koyama et al., 2013; Shrivastava et al., 2007) 
or by reducing inflammatory cells infiltration (Yang et 
al., 2007). 
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5.  Conclusion:  
Acute liver injury is a debilitating disorder that is 
associated with loss of synthetic and detoxifying 
functions of liver and can quickly lead to multiple organ 
failure and death. Tiron is a potential cytoprotective 
drug that acts mainly through inhibiting inflammatory 
response mediated by kupffer cells and alleviating 
oxidative stress. In the current study, tiron improved 
liver function and decreased cytotoxicity and 
inflammation. Tiron mildly improved liver’s synthetic 
function and substantially improved hepatic excretory 
functions. Tiron dramatically improved anti-oxidant 
defense system. The findings suggest that the use of 
tiron can be potentially beneficial in prevention of acute 
liver injury and that it has anti-inflammatory and anti-
oxidant effects. 
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